Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Adavosertib

Generic Name: Adavosertib

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₃₂N_₈O_₂

CAS Number: 955365-80-7

Unique Ingredient Identifier: K2T6HJX3I3

Overview

MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

Background

MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

Phase 2

Completed

Posted: 2017/08/18

Sponsor:National Cancer Inst...

ID:NCT03253679

WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer

Phase 1

Completed

Posted: 2017/01/23

Sponsor:University of Birmin...

ID:NCT03028766

CISPLATIN + AZD-1775 In Breast Cancer

Phase 2

Completed

Posted: 2017/01/06

Sponsor:Dana-Farber Cancer I...

ID:NCT03012477

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Phase 2

Completed

Posted: 2016/10/19

Sponsor:AstraZeneca

ID:NCT02937818

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

Phase 1

Completed

Posted: 2016/09/19

Sponsor:NYU Langone Health

ID:NCT02906059

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Adavosertib Shows Promise in Uterine Serous Carcinoma Despite Tolerability Challenges

15 days ago

The phase 2b ADAGIO trial demonstrated adavosertib's antitumor activity with a 26% objective response rate in patients with recurrent or persistent uterine serous carcinoma, though median progression-free survival was only 2.8 months.

Schrödinger Unveils Promising Preclinical Data for Novel Cancer Therapeutics at AACR 2025

2 months ago

Schrödinger presented preclinical data for SGR-3515, a Wee1/Myt1 co-inhibitor showing superior anti-tumor activity compared to monotherapy inhibitors, with optimized dosing schedules that preserve efficacy while minimizing side effects.

Phase IIb ADAGIO Trial: Adavosertib Shows Limited Efficacy with High Toxicity in Uterine Serous Carcinoma

4 months ago

The Wee1 inhibitor adavosertib demonstrated modest activity with a 26% objective response rate in patients with recurrent or persistent uterine serous carcinoma in the phase IIb ADAGIO trial.

Eflornithine (Iwilfin) Approved for High-Risk Neuroblastoma to Reduce Relapse Risk

6 months ago

Eflornithine (Iwilfin) is now FDA-approved to reduce the risk of relapse in high-risk neuroblastoma patients who have shown partial response to prior therapies.

Mathematical Model Identifies PARP Inhibitor Resistance Biomarkers in Triple-Negative Breast Cancer

6 months ago

A novel mathematical model was developed to analyze tumor growth dynamics in triple-negative breast cancer (TNBC) patient-derived xenografts treated with olaparib.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy